Folr1 Car T-Cells
Recurrent Childhood Acute Myeloid Leukemia
Fred Hutchinson Cancer CenterCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
51 Active assets in the Recurrent Childhood Acute Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Joanna Yi | Phase 3 | BBB |
Cytosin-Arabinosid Children's Oncology Group | Phase 3 | BBB |
FILGRASTIM National Cancer Institute (NCI) | Phase 3 | BBB |
METHOTREXATE Children's Oncology Group | Phase 3 | BBB |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 3 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →